Skip to main content
NCBI home page
Current Therapeutic Research, Clinical and Experimental logoLink to Current Therapeutic Research, Clinical and Experimental
. 2004 Jul;65(4):345–352. doi: 10.1016/j.curtheres.2004.06.001

Chemopreventive effect of nonsteroidal anti-inflammatory drugs on the development of a new colorectal polyp or adenoma in a high-risk population: a meta-analysis

Emine Arzu Kanik 1,*, Hakan Canbaz 2, Tahsin Colak 2, Suha Aydin 2
PMCID: PMC3964583  PMID: 24672089

Abstract

Background

Although many experimental, epidemiologic, and clinical studies have suggested that aspirin or other nonsteroidal anti-inflammatory drugs (NSAIDs) are effective in reducing and preventing colorectal adenomas, randomized, controlled trials (RCTs) are still being carried out to obtain statistically reliable results.

Objective

The aim of this meta-analysis was to review long-term, prospective RCTs investigating the effect of NSAIDs on the relative risk (RR) for developing ≥1 new colorectal polyp or adenoma in a high-risk population.

Methods

We conducted a comprehensive search of MEDLINE, PubMed, and other electronic databases (including Inter-Science, Science Direct, Ebsco, Synergy, and Proquest) (key terms: nonsteroidal anti-inflammatory drugs, aspirin, colorectal, and polyps; years: 1974–2004) for English-language articles. Eligible studies were analyzed in terms of demographic data, adverse effects, and effect of NSAIDs on the RRs.

Results

Four long-term, prospective RCTs were used in the statistical analysis. A total of 2069 high-risk patients were enrolled; 1880 patients completed the studies, and 1127 were in active-treatment groups (aspirin 81–325 mg/d or sulindac 150–300 mg/d). Our meta-analysis of these studies revealed that the overall RR for developing ≥ 1 new colorectal polyp or adenoma was significantly reduced by using aspirin or other NSAIDs (RR = 0.809; 95% CI, 0.718–0.912).

Conclusions

The results of this meta-analysis suggest that regular use of aspirin 81 to 325 mg/d or sulindac 150 to 300 mg/d for ≥1 year was associated with a decrease in the RR for developing ≥ 1 new colorectal polyp or adenoma to 0.80 (95% CI, 0.718–0.912) in patients at high risk.

Keywords: aspirin, colorectal adenoma, colorectal cancer, meta-analysis, NSAIDs, relative risk

Full Text

The Full Text of this article is available as a PDF (424.5 KB).

References

  • 1.García Rodríguez LA, Huerta-Alvarez C. Reduced incidence of colorectal adenoma among long-term users of nonsteroidal antiinflammatory drugs: A pooled analysis of published studies and a new population-based study. Epidemiology. 2000;11:376–381. doi: 10.1097/00001648-200007000-00003. [DOI] [PubMed] [Google Scholar]
  • 2.Sturmer T, Glynn RJ, Lee IM. Aspirin use and colorectal cancer: Post-trial follow-up data from the Physicians Health Study. Ann Intern Med. 1998;128:713–720. doi: 10.7326/0003-4819-128-9-199805010-00003. [DOI] [PubMed] [Google Scholar]
  • 3.Giovannucci E, Rimm EB, Stampfer MJ. Aspirin use and the risk for colorectal cancer and adenoma in male health professionals. Ann Intern Med. 1994;121:241–246. doi: 10.7326/0003-4819-121-4-199408150-00001. [DOI] [PubMed] [Google Scholar]
  • 4.Giovannucci E, Egan KM, Hunter DJ. Aspirin and the risk of colorectal cancer in women. N Engl J Med. 1995;333:609–614. doi: 10.1056/NEJM199509073331001. [DOI] [PubMed] [Google Scholar]
  • 5.Pollard M, Luckert PH. Prolonged antitumor effect of indomethacin on autochthonous intestinal tumors in rats. J Natl Cancer Inst. 1983;70:1103–1105. [PubMed] [Google Scholar]
  • 6.Lew JI, Guo Y, Kim RK. Reduction of intestinal neoplasia with adenomatous polyposis coli gene replacement and COX-2 inhibition is additive. J Gastrointest Surg. 2002;6:563–568. doi: 10.1016/s1091-255x(01)00042-7. [DOI] [PubMed] [Google Scholar]
  • 7.Wilson LC, Baek SJ, Call A, Eling TE. Nonsteroidal anti-inflammatory drug—activated gene (NAG-I) is induced by genistein through the expression of P53 in colorectal cancer cells. Int J Cancer. 2003;105:747–753. doi: 10.1002/ijc.11173. [DOI] [PubMed] [Google Scholar]
  • 8.Laine L. The gastrointestinal effects of nonselective NSAIDs and COX-2-selective inhibitors. Semin Arthritis Rheum. 2002;32:25–32. doi: 10.1053/sarh.2002.37217. [DOI] [PubMed] [Google Scholar]
  • 9.Elder DJ, Halton DE, Playle LC, Paraskeva C. The MEK/ERK pathway mediates COX2-selective NSAID-induced apoptosis and induced COX-2 protein expression in cob-rectal carcinoma cells. Int J Cancer. 2002;99:323–327. doi: 10.1002/ijc.10330. [DOI] [PubMed] [Google Scholar]
  • 10.Pendlebury S, Duchesne F, Reed KA. A trial of adjuvant therapy in colorectal cancer: The VICTOR trial. Clin Colorectal Cancer. 2003;3:58–60. doi: 10.3816/CCC.2003.n.013. [DOI] [PubMed] [Google Scholar]
  • 11.Baron JA, Cole BF, Sandler RS. A randomized trial of aspirin to prevent colorectal adenomas. N Engl J Med. 2003;348:891–899. doi: 10.1056/NEJMoa021735. [DOI] [PubMed] [Google Scholar]
  • 12.Sandler RS, Halabi S, Baron JA. A randomized trial of aspirin to prevent colorectal adenomas in patients with previous colorectal cancer. N Engl J Med. 2003;348:883–890. doi: 10.1056/NEJMoa021633. [DOI] [PubMed] [Google Scholar]
  • 13.Benamouzig R, Deyra J, Martin A. Daily soluble aspirin and prevention of colorectal adenoma recurrence: One-year results of the APACC trial. Gastroenterology. 2003;125:328–336. doi: 10.1016/s0016-5085(03)00887-4. [DOI] [PubMed] [Google Scholar]
  • 14.Giardieblo FM, Yang VW, Hylind LM. Primary chemoprevention of familial adenomatous polyposis with sulindac. N Engl J Med. 2002;346:1054–1059. doi: 10.1056/NEJMoa012015. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 15.Paganini-Hill A. Aspirin and the prevention of colorectal cancer: A review of the evidence. Semin Surg Oncol. 1994;10:158–164. doi: 10.1002/ssu.2980100303. [DOI] [PubMed] [Google Scholar]
  • 16.Giardiello FM, Hamilton SR, Krush AJ. Treatment of colonic and rectal adenomas with sulindac in familial adenomatous polyposis. N Engl J Med. 1993;328:1313–1316. doi: 10.1056/NEJM199305063281805. [DOI] [PubMed] [Google Scholar]
  • 17.Steinbach G, Lynch PM, Phillips RK. The effect of celecoxib, a cyclooxygenase-2 inhibitor, in familial adenomatous polyposis. N Engl J Med. 2000;342:1946–1952. doi: 10.1056/NEJM200006293422603. [DOI] [PubMed] [Google Scholar]
  • 18.Takayama T, Katsuki S, Takahashi Y. Aberrant crypt foci of the colon as precursors of adenoma and cancer. N Engl J Med. 1998;339:1277–1284. doi: 10.1056/NEJM199810293391803. [DOI] [PubMed] [Google Scholar]
  • 19.Sandler RS, Galanko JC, Murray SC. Aspirin and nonsteroidal anti-inflammatory agents and risk for colorectal adenomas. Gastroenterology. 1998;114:441–447. doi: 10.1016/s0016-5085(98)70526-8. [DOI] [PubMed] [Google Scholar]
  • 20.Martin C, Connelly A, Keku TO. Nonsteroidal anti-inflammatory drugs, apoptosis, and colorectal adenomas. Gastroenterology. 2002;123:1770–1777. doi: 10.1053/gast.2002.37053. [DOI] [PubMed] [Google Scholar]
  • 21.Sample DA, Sinicrope PS, Wargovich MJ, Sinicrope FA. Post-study aspirin intake and factors motivating participation in a colorectal cancer chemoprevention trial. Cancer Epidemiol Biomarkers Prey. 2002;11:281–285. [PubMed] [Google Scholar]
  • 22.Ladabaum U, Chopra CL, Huang G. Aspirin as an adjunct to screening for prevention of sporadic colorectal cancer. A cost-effectiveness analysisAnn Intern Med. 2001;135:769–781. doi: 10.7326/0003-4819-135-9-200111060-00007. [DOI] [PubMed] [Google Scholar]
  • 23.Benamouzig R, Yoon H, Little J. APACC, a French prospective study on aspirin efficacy in reducing colorectal adenoma recurrence: Design and baseline findings. Eur J Cancer Prev. 2001;10:327–335. doi: 10.1097/00008469-200108000-00006. [DOI] [PubMed] [Google Scholar]
  • 24.Schatzkin A, Lanza E, Freedman LS. The polyp prevention trial I: Rationale, design, recruitment, and baseline participant characteristics. Cancer Epidemiol Biomarkers Prev. 1996;5:375–383. [PubMed] [Google Scholar]
  • 25.Hunter JE, Schmidt FL. Sage; 1990. Methods of Meta-Analysis: Correcting Error and Bias in Research Findings. [Google Scholar]
  • 26.Egger M, Smith GD, Schneider M, Minder C. Bias in meta-analysis detected by a simple, graphical test. BMJ. 1997;315:629–634. doi: 10.1136/bmj.315.7109.629. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 27.Chalmers TC. Problems induced by meta-analyses. Stat Med. 1991;10:971–980. doi: 10.1002/sim.4780100618. [DOI] [PubMed] [Google Scholar]
  • 28.Sacks H, Chalmers TC, Smith H., Jr Randomized versus historical controls for clinical trials. Am J Med. 1982;72:233–240. doi: 10.1016/0002-9343(82)90815-4. [DOI] [PubMed] [Google Scholar]
  • 29.Schulz KF, Chalmers I, Hayes RJ, Altman DG. Empirical evidence of bias. Dimensions of methodological quality associated with estimates of treatment effects in controlled trialsJAMA. 1995;273:408–412. doi: 10.1001/jama.273.5.408. [DOI] [PubMed] [Google Scholar]

Articles from Current Therapeutic Research, Clinical and Experimental are provided here courtesy of Elsevier

RESOURCES